# Pilot Study to Evaluate the Safety and Analgesic Activity of M40403 Co-Administered With an Opioid Agent for Cancer Pain

> **NCT00101621** · PHASE2 · TERMINATED · sponsor: **MetaPhore Pharmaceuticals** · enrollment: 24 (—)

## Conditions studied

- Cancer
- Pain

## Interventions

- **DRUG:** M40403

## Key facts

- **NCT ID:** NCT00101621
- **Lead sponsor:** MetaPhore Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2004-08
- **Primary completion:** —
- **Final completion:** 2005-08
- **Target enrollment:** 24 (—)
- **Last updated:** 2006-02-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00101621

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00101621, "Pilot Study to Evaluate the Safety and Analgesic Activity of M40403 Co-Administered With an Opioid Agent for Cancer Pain". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT00101621. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*